Patient Guide: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 216 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05455320
Status: ACTIVE_NOT_RECRUITING
Condition: Relapsed or Refractory Multiple Myeloma
Phase: PHASE3

Where You Can Participate

This study is available at 216 locations across the country.

Top locations include:
  • • Tucson, Arizona
  • • Little Rock, Arkansas
  • • Norwalk, Connecticut
  • • And 213 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment - Join Clinical Trial NCTNCT05455320

How to Join This Clinical Trial - NCTNCT05455320

Learn how to participate in this PHASE3 trial studying an investigational therapy for Relapsed or Refractory Multiple Myeloma. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Relapsed or Refractory Multiple Myeloma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Relapsed or Refractory Multiple Myeloma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT05455320 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 216 locations. Find a study site near you:

Clinical Research Site

Tucson, Arizona 85719 - United States

Status: Contact for availability

Clinical Research Site

Little Rock, Arkansas 72205 - United States

Status: Contact for availability

Clinical Research Site

Norwalk, Connecticut 06850 - United States

Status: Contact for availability

Clinical Research Site

Washington, District of Columbia 20007 - United States

Status: Contact for availability

Clinical Research Site

Washington, District of Columbia 20037 - United States

Status: Contact for availability

Clinical Research Site

Hollywood, Florida 33021 - United States

Status: Contact for availability

Clinical Research Site

Miami, Florida 33136 - United States

Status: Contact for availability

Clinical Research Site

Chicago, Illinois 60612 - United States

Status: Contact for availability

Clinical Research Site

Westwood, Kansas 66205 - United States

Status: Contact for availability

Clinical Research Site

New Orleans, Louisiana 70112 - United States

Status: Contact for availability

And 206 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Relapsed or Refractory Multiple Myeloma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships